No Data
Shareholder Shanghai Yixing has reduced its shareholding by 0.46% in Shanghai Yizhong (688091.SH).
Shanghai Yizhong (688091.SH) announced that as of March 25, 2025, the Shareholder Shanghai Yixing has already passed...
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Shanghai Yizhong: Announcement on the 2024 Annual Results Report of Shanghai Yizhong Pharmaceutical Co., Ltd.
Shanghai Yizhong Pharmaceutical Co., Ltd. 2024 Annual Results Express Announcement
Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Shanghai Yizhong Pharmaceutical Co., Ltd. 2024 Annual Results Forecast Announcement